Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...

Pharmaceutical giant Novo Nordisk will lower the cost of several of its insulin products by up to 75% next year. Effective January 2024, the list price for insulin brands, including NovoLog and ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs).

Analog insulin will still be available in the pen format under Novo's plan. Back in June, The New York Times reported that South Africa’s public health system had run out of human insulin pens ...

LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... income countries will not suffer from the halting of insulin pen production, because the company is continuing to make ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

In the U.S., Novo Nordisk’s recent decision ... They’re filled in pen devices that are similar to the pens that many insulin products come in. As demand for GLP-1s continues to climb, patients ...

Building upon its existing work with IBM Watson Health and Glooko, Novo Nordisk aims to integrate insulin dosing data from connected pen devices with its partners' open ecosystems and diabetes ...

South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...